Founder Directory
Built by Keitoto
Founders2
Known for these resultsRole100%Role is parsed from founder titles in yc.db. Known for 100% of these rows — the rest have no title at all, mostly 2019–2023. Those rows stay in the result and are counted as Unknown, never as No.Bio100%Bio coverage: 100% of these founders have a bio on their YC profile. Every bio-derived facet (ex-company, school, credentials, discipline) is Unknown for the rest.Ex-company0%Ex-company is matched from bios with employment context (ex-, formerly, worked at). 0% of these rows have at least one match.School100%School is matched from bios, case-sensitive for acronyms. 100% of these rows have at least one match.
- David van Dijk@david_van_dijkFounder/CEO · CellTypeW26Healthcare · New York
- Ivan VrkicFounder/CTO · CellTypeW26Healthcare · New York
FOUNDERROLEBATCHINDUSTRYLOCATIONTEAMX_url
David van DijkCellTypeFounder/CEOWinter 2026HealthcareNew York, United States2https://x.com/david_van_dijkIvan VrkicCellTypeFounder/CTOWinter 2026HealthcareNew York, United States2—
Showing 1–2 of 2 founders
Ivan Vrkic
Founder/CTO·CellType
PRIMARY INFO
RoleFounder/CTO
Team size2
BatchWinter 2026
LocationNew York, United States
Company statusActive
StageEarly
BIO
Co-Founder @ CellType (W26). ML @ Yale & EPFL. Building the next-generation agentic drug company. Co-developed our core technology Cell2Sentence at Yale and published at ICML. Previously led large-scale foundation model training at a biotech startup and built software to control CERN's Large Hadron Collider.
Ex-company, school and discipline below are derived from this bio. Nothing is inferred when the bio is missing.
BACKGROUND
Credentialsnone mentioned
DisciplineEngineerKeyword match from the bio text, not a classifier.
TRACK RECORD
First YC company on record
COMPANY CONTEXT
CellType
The agentic drug company. We simulate human biology.
Co-foundersDavid van Dijk@david_van_dijk
